Cholinergic Modulation of Cognition and Emotion in Mood Disorders
情绪障碍中认知和情绪的胆碱能调节
基本信息
- 批准号:8556944
- 负责人:
- 金额:$ 63.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcetylcholineAdultAffectAffectiveAlcohol abuseAmericanAnteriorAnti-CholinergicsAntidepressive AgentsAnxiety DisordersAreaArea Under CurveAttentionBehavioralBiological MarkersBipolar DisorderBrainBrain imagingBrain regionClassificationClinicalClinical MarkersClinical ResearchClinical TrialsCognitionCognitiveCollectionComplementDataDepressed moodDisease remissionDoctor of PhilosophyDoseDrug FormulationsDrug KineticsEmotionalEmotionsEnvironmentFaceFamily history ofFunctional ImagingFunctional Magnetic Resonance ImagingGenderHousingHypersensitivityImageImpaired cognitionIndividualInfusion proceduresMaintenanceMajor Depressive DisorderMediatingMemoryMemory impairmentMental DepressionMood DisordersMoodsMuscarinic Acetylcholine ReceptorMuscarinic AntagonistsMuscarinicsNoseOutcomeParticipantPatient Self-ReportPatientsPatternPerformancePharmacy facilityPlacebosPopulationPredictive ValueProceduresProcessProtocols documentationPublic HealthPublishingReaction TimeRecruitment ActivityReportingRetrievalRoleRouteSamplingScopolamineShort-Term MemoryStimulusSymptomsSystemTestingTherapeuticTreatment outcomeUnited StatesUnited States National Institutes of HealthValidationVisual CortexWomanbasebehavioral impairmentblood oxygenation level dependent responsecholinergiccognitive functiondepressive symptomsdisabilityemotional stimulusexperienceimaging modalityimprovedindexingmemory encodingmenneural circuitneural recruitmentrelating to nervous systemresponseselective attentionshowing emotionsingle episode major depressive disorderstimulus processingtreatment responsevisual processvisual processing
项目摘要
Clinical Studies:The role of cholinergic system in mood disorders has been highlighted recently through our demonstration that blocking cholinergic muscarinic activity with scopolamine produces rapid antidepressant effects. Our early studies identified an antidepressant effect of scopolamine in both MDD and BD patients. Significant (p< 0.001) clinical improvement occurred following a single infusion of scopolamine. Over the course of the clinical trial, 70% of patients experience a full response (50% reduction in symptoms) and over 50% experience remission of symptoms.A replication of our original finding was published in an independent MDD sample of patients. Moreover, we observed that while men and women show significant clinical improvement following scopolamine, women show a larger response than do men (p< 0.01). Recently, we conducted a pharmacokinetic study to identify an alternative route of scopolamine administration. The NIH pharmacy developed a nasal spray formulation, and over the past year we completed the collection of pharmacokinetic data to identify the nasal spray dose that most closely approximates the area-under-the-curve obtained with the i.v. administration. These samples currently are being processed by our collaborator, Irving Wainer, PhD. Clinical trials utilizing this route of administration potentially will begin within the next year.
Cognitive and Imaging Studies: Behavioral and cognitive features of depression are associated primarily with the processing of affective information. A consistently reported finding is a mood congruent processing bias, which is defined as a tendency to show a bias for processing negative as compared to positive or neutral information. The mood congruent processing bias observed in MDD can be characterized within the framework of cholinergic system and stimulus processing mechanisms. The biased processing of negative or sad information is consistent with over-active cholinergic function in depression resulting in the over-representation of negative information. We would hypothesize that competition among stimuli in the environment engages cholinergic system, and the overactive system alters the bias preferentially towards negative stimuli in MDD. We are utilizing functional brain imaging methods to elucidate the role of the cholinergic system in stimulus processing biases. We characterized behaviorally a stimulus processing bias associated with a selective attention task where face and house stimuli are presented simultaneously. Faster reaction time when attending to faces (vs houses) reflects a stimulus process bias towards faces. Scopolamine selectively increased reaction time when attending to face stimuli with no change when attending to houses, reflecting a stimulus specific shift in the processing bias. The brain regions in visual processing areas which show a bias towards faces (larger response to faces than to houses) during placebo, reduce the bias during scopolamine, a result that complements the behavioral finding. In brain regions that show a bias for processing houses during placebo, no change is observed following scopolamine. Acetylcholine also influences working memory (WM) function through stimulus processing mechanisms and particularly is critical to the encoding of information through stimulus processing mechanisms. We evaluated the influence of blocking cholinergic muscarinic activity on neural responses during WM encoding as the attended stimulus feature was modulated in a fMRI study. During the task a picture of a face was shown (encoding) followed by a delay component (maintenance) then another picture of a face (test/retrieval). Healthy participants were instructed to match the test stimulus to either the identity or the emotional expression of the encoded face. Neural activity associated with encoding was estimated for the emotion and identity task conditions. Blocking cholinergic muscarinic receptors preferentially reduced BOLD response during encoding selectively when attending to the emotional stimulus content, with no change when attending to identity. This finding suggests that the more salient stimulus feature (i.e. emotion) is more susceptible to cholinergic modulation.
Biomarker of Treatment Response
Clinical Markers of Treatment Response. We evaluated the potential for baseline clinical ratings to predict treatment response to scopolamine. We conducted a discriminant function analysis to determine if a linear combination of self-report mood-ratings could discriminate treatment responders from non-responders. Moreover, we used a validation procedure to determine if we could predict at baseline whether individual patients would be a responder or a non-responder following scopolamine treatment. The disciminant function identified a set of 4 or 5 clinical ratings that, when combined into a linear function, classified 86% of unipolar patients as responders or non-responders (p= 0.002); the discriminant function scores differed significantly between the responders and non-responders (p< 0.001). The validation analysis was able to correctly predict classification in over 70% of MDD patients. Similarly, the discriminant function classified 88% of BP patients, and the discriminant fuction scores differed significantly between the responders and non-responders (p< 0.001). The validation analysis in the BP group was able to correctly predict classification in over 85% of the patients. These results indicate that baseline self-report mood-ratings obtained prior to treatment can predict response outcome to scopolamine.We also are considering potential clinical or patient variables that might contribute to the identification of patients who will response to scopolamine treatment. Previously we demonstrated that gender influenced treatment outcome and we currently are evaluating other variables including family history of mood disorders; family history of alcohol abuse; comorbid anxiety disorder etc. These analyses are underway.
Functional Imaging Markers of Treatment Response. We evaluated whether the functional brain response during WM may predict the antidepressant response to scopolamine. A group of MDD patients participated in a fMRI study using the WM task described above. Imaging data were obtained at baseline and following scopolamine. Neural activity (at baseline) associated with each separate task component was correlated with the magnitude of treatment response at study end. Correlations (p< 0.01) were seen in visual processing areas for the encoding and retrieval components of WM, selectively during the emotion task with no correlation in the identity task. Following treatment with scopolamine, changes in neural response in these same brain regions also correlated with the magnitude of response. We show that baseline levels of neural activity in visual processing areas reflect potential for response to treatment with scopolamine. The cortical regions that show baseline predictive value for treatment response also respond to cholinergic modulation, which argues that baseline differences are cholinergically mediated. Using a selective attention task, we also conducted analyses to evaluate if a brain response index that reflects emotional processing biases also predicts treatment response. We found that neural activity at baseline (prior to treatment) in both the anterior cingulated cortex and visual processing areas (which overlap with areas identified in the working memory task) correlated with subsequent treatment response to scopolamine. Interestingly, the pattern of correlation was opposite in the anterior cingulated and in visual cortex. These findings indicate that difference in response patterns based on emotional content of information has the potential to predict subsequent response to treatment with scopolamine.
临床研究:胆碱能系统在情绪障碍中的作用最近得到了强调,我们的研究表明,用东莨菪碱阻断胆碱能毒蕈碱活性可以产生快速的抗抑郁作用。我们的早期研究发现东莨菪碱对重度抑郁症和双相障碍患者都有抗抑郁作用。单次输注东莨菪碱后出现显著的临床改善(p< 0.001)。在临床试验过程中,70%的患者完全缓解(症状减轻50%),超过50%的患者症状缓解。在一个独立的重度抑郁症患者样本中发表了我们原始发现的复制。此外,我们观察到,尽管男性和女性在服用东莨菪碱后均表现出显著的临床改善,但女性的反应大于男性(p< 0.01)。最近,我们进行了一项药代动力学研究,以确定东莨菪碱给药的替代途径。NIH药房开发了一种鼻喷剂配方,在过去的一年里,我们完成了药代动力学数据的收集,以确定最接近静脉注射获得的曲线下面积的鼻喷剂剂量。这些样品目前正在由我们的合作者欧文·韦纳博士处理。利用这种给药途径的临床试验可能会在明年开始。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carlos Zarate其他文献
Carlos Zarate的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carlos Zarate', 18)}}的其他基金
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect
快速谷氨酸调节剂
- 批准号:
8556954 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression
抗谷氨酸药物对双相抑郁症的抗抑郁功效
- 批准号:
7735168 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Neurobiology and Target validation of novel therapeutic agents in mood disorders
情绪障碍新型治疗药物的神经生物学和靶标验证
- 批准号:
8940006 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect
谷氨酸能调节剂具有快速和持续的抗抑郁作用
- 批准号:
10703926 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect
谷氨酸能调节剂具有快速和持续的抗抑郁作用
- 批准号:
10012699 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Target validation of novel therapeutic agents in mood disorders
情绪障碍新型治疗药物的靶点验证
- 批准号:
8158161 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect
快速谷氨酸调节剂
- 批准号:
8342152 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Neurobiology and Target validation of novel therapeutic agents in mood disorders
情绪障碍新型治疗药物的神经生物学和靶标验证
- 批准号:
8745751 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect
快速谷氨酸调节剂
- 批准号:
8939983 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect
谷氨酸能调节剂具有快速和持续的抗抑郁作用
- 批准号:
9357286 - 财政年份:
- 资助金额:
$ 63.58万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 63.58万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 63.58万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 63.58万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 63.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 63.58万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 63.58万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 63.58万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 63.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 63.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 63.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)